.jpg)
Zentiva, a pharmaceutical company that develops, manufactures, and markets a wide range of generic and over-the-counter (OTC) medicines, and Aboca, an Italian healthcare company focused on health solutions made from 100% natural products, have entered into an agreement for the transfer of five of Aboca’s historic brands — Propol2 EMF, Ruscoven, Serenil, Fisiodepur, and Finocarbo — to Zentiva.
The transaction will allow Aboca to concentrate more on its other key brands and the development of new products, while enabling Zentiva to expand access to well-known natural treatments throughout Europe. Additionally, the acquisition supports Zentiva's goal of establishing itself as a leading player in the Consumer Healthcare (CHC) sector.
CMS assisted Zentiva with a team led by partner Daniela Murer, who, together with counsel Alessandra Cuni and associate Sara Tammarazio, handled the corporate aspects, and partner Stefano Giuliano, who, assisted by senior associates Federica Fiorani and Marta Puccini, handled the tax aspects. The team was coordinated by partner Matia Campo.
Bird & Bird acted on behalf of Aboca with a team led by partner Claudia Ricciardi, supported by counsel Paola Ruggiero and associate Giulia Velcich (IP matters), partner Calogero Porrello and associate Laura Pallanza (corporate aspects), and partner Gaetano Salvioli together with senior associate Dario D’Alò (tax matters).
